Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Beam Therapeutics (BEAM) Shares Outstanding (Diluted Average) (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Shares Outstanding (Diluted Average) for 7 consecutive years, with $98.9 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 20.16% to $98.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $98.9 million through Dec 2025, up 20.16% year-over-year, with the annual reading at $98.9 million for FY2025, 20.16% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $98.9 million at Beam Therapeutics, down from $102.6 million in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $102.6 million in Q3 2025, with the low at $60.2 million in Q1 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $77.1 million, with a median of $76.1 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Diluted Average) skyrocketed 44.94% in 2021, then rose 5.2% in 2023.
  • Over 5 years, Shares Outstanding (Diluted Average) stood at $64.2 million in 2021, then increased by 9.01% to $70.0 million in 2022, then rose by 10.19% to $77.2 million in 2023, then grew by 6.69% to $82.3 million in 2024, then grew by 20.16% to $98.9 million in 2025.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $98.9 million, $102.6 million, and $95.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.